SCHEMBL2979351

SCHEMBL2979351

O=C(NC1CC1)c1ccc(-c2ccccc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 1.00
NPC1 O15118 5/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
SMYD3 Q9H7B4 2/20 0.84
CYP46A1 Q9Y6A2 1/20 0.67
CTSL P07711 1/20 0.61
CTSB P07858 1/20 0.61
CTSK P43235 1/20 0.61
DRD2 P14416 1/20 0.59
DRD4 P21917 1/20 0.59
MAPT P10636 1/20 0.58
CTDSP1 Q9GZU7 1/20 0.58
TRPM8 Q7Z2W7 1/20 0.54
BACE1 P56817 1/20 0.53
CYP1A2 P05177 1/20 0.53
HPGD P15428 1/20 0.53
CYP2C19 P33261 1/20 0.53
GAA P10253 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8161568 0.93 NPC1 (0.87) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL23575862 0.92 SMYD3 (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL19701285 0.92 SMYD3 (1.00) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL8167649 0.92 RAB9A (0.84) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2983895 0.91 NPC1 (0.84) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL22289346 0.91 NPC1 (0.84) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL22308180 0.91 NPC1 (0.84) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL27579055 0.89 NPC1 (0.79) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL2230140 0.88 NPC1 (0.79) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL124395 0.88 NPC1 (0.79) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115710287-B Ring-opening boronation reaction method for cyclopropane compound under no metal catalysis 中国科学院兰州化学物理研究所 2024-01-09 CN disclosed
CN-115710287-A Ring-opening boronization reaction method of cyclopropane compound under condition of no metal catalysis 中国科学院兰州化学物理研究所 2023-02-24 CN disclosed
US-7781591-B2 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC (US) 2010-08-24 US disclosed
EP-2121621-A1 LXR AND FXR MODULATORS Exelixis, Inc. (US) 2009-11-25 EP disclosed
WO-2008073825-A1 LXR AND FXR MODULATORS EXELIXIS, INC. (US) 2008-06-19 WO disclosed
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors WYETH LLC 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287708-A1 Substituted 3-cyanopyridines as protein kinase inhibitors CNKSR1, MAP3K1, MAP3K7 RAB9A 2777/4885NPC1 1800/4885SMN1; SMN2 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.